الفهرس 
Introduction & Review of LiteratureOnly 14 pages are availabe for public view
 |  | from | 141 |  |  |
| | | from | 141 | | |
Abstract
Schistosomiasis is one of the endemic diseases in Egypt for several of years. Praziquantel considered being the only chemotherapy used against schistosomiasis. Although praziquantel is effective against the parasite, but it does not show any vital role against reinfection. Another chemotherapies seem to be effective, one of these chemotherapies is Ro 15-5458 ([10-(2-diethylamino) ethyl] -9-acridanone (thiazolidin-2-ylidene) hydrazine, CAS 92928-74-7) which is effective against schistosome infection especially against larvae stage, but it does not available with praziquantel. In this study, RO was given to mice with a dose 100 mg/kg at day six of infection with repeated rounds of infection and treatment. Different parameters were studied as: (1) IgG and IgM levels in serum; (2) FOXP3 levels in spleen and liver using flow cytometric technique; (3) ALT, AST gene expression and also their levels in serum; (4) LDH, bilirubin and total protein; (5) Histological and Ultrastructural analysis a part from granuloma to determine liver integrity. At the end, this study showed some evidence of immune regulation associated with the using of Ro treatment and liver integrity after treatment. This study recommended to use Ro as a new treatment drug against schistosomiasis and also recommended the early diagnosis to determine the treatment. The present study considered to be an initial study that revealed new antigens against antibodies that do not appear during the infection and it may be useful in the future in the development of anti- pathological vaccines.